Antileukemic Effect of Interleukin-7-Transduced Bone Marrow Stromal Cells in Mice Following Allogeneic T-Cell-Depleted Bone Marrow Transplantation

Li, A.L.; Li, C.; Feng, Ying; Yuan, Gang; Wang, G.M.; Hao, Jie; Gao, Xiang; Xie, Sai‐Sai

doi:10.1016/j.transproceed.2005.03.088

Cited by 5 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors concluded again that IL-7 plays a major role in the regulation of ALL cell proliferation. Gene therapy expressing IL-7 with transduced bone marrow cells was also observed to be effective in in vivo of allogenic bone marrow transplantation [58]. In the study by Consolini et.…”

Section: Malignancy Treatmentmentioning

confidence: 98%

Interleukin-8 and Interleukin-17 for Cancer

Zarogoulidis¹,

Katsikogianni²,

Tsiouda³

et al. 2014

Cancer Investigation

103

View full text Add to dashboard Cite

Interleukin 7 and 15 are considered powerful pro-inflammatory cytokines, they have the ability to destabilize chromosomes and induce tumorigenesis. Additionally, they can control malignancy proliferation by influencing the tumor microenvironment and immune system. Immunotherapy has been proposed as a treatment modality for malignancy for over a decade; the exact mechanisms of action and pathways are still under investigation. Interleukin 7 and 15 have been extensively investigated in hematological malignancies since their mode of action influences the stimulation of the immune system in a more direct way than other malignancies such as lung, melanoma, and breast, renal and colorectal cancer.

show abstract

Section: Malignancy Treatmentmentioning

confidence: 98%

Interleukin-8 and Interleukin-17 for Cancer

Zarogoulidis¹,

Katsikogianni²,

Tsiouda³

et al. 2014

Cancer Investigation

103

View full text Add to dashboard Cite

show abstract

“…In addition IL-7 can promote delayed-type hypersensitivity reactions in mice. 39 Effects of IL-7 in rodents and primates differ markedly in some aspects, as demonstrated by studies of IL-7Ra deficient humans and mice. 16 28 30 Thus analysis of IL-7 induced effects in primates is also important.…”

Section: Role Of Il-7 In Immunity and Inflammationmentioning

confidence: 99%

Interleukin-7 induced immunopathology in arthritis

Hartgring

Bijlsma

Lafeber

et al. 2006

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

“…A recombinant human CD40L, which has been used in clinical trials for patients with pancreatic cancer, could be used to activate the innate immune system . Given that CTLA‐4 blockers induce ICOS , which further improves the function and survival of anti‐tumor Th17 cells , administering an ICOS agonist might also enhance treatment outcome in patients.…”

Section: Future Combination Immunotherapies To Bolster Tumor Regressionmentioning

confidence: 99%

“…Regulatory B cells can also dampen an immune responses and thus their removal with rituximab or anti‐CD19 CAR T cells might enhance cell therapy . To bolster the infused T cells, homeostatic cytokines IL‐7, IL‐15, or IL‐21 and their respective complexes could be administered systemically to support the tumor‐reactive lymphocytes, as these cytokines are of low basal level in cancer patients . Approaches aimed at neutralizing specific immunoregulatory mechanisms or the addition of reagents targeting immune checkpoints to BiTEs or CAR T‐cell therapy approaches may overcome immune suppression and enhance T‐cell‐mediated tumor regression.…”

Section: Future Combination Immunotherapies To Bolster Tumor Regressionmentioning

confidence: 99%

Novel immunotherapies for hematologic malignancies

Nelson

Paulos

2014

Immunological Reviews

View full text Add to dashboard Cite

Summary The immune system is designed to discriminate between self and tumor tissue. Through genetic recombination, there is fundamentally no limit to the number of tumor antigens that immune cells can recognize. Yet, tumors use a variety of immunosuppressive mechanisms to evade immunity. Insight into how the immune system interacts with tumors is expanding rapidly and has accelerated the translation of immunotherapies into medical breakthroughs. Herein, we appraise the state of the art in immunotherapy with a focus on strategies that exploit the patient’s immune system to kill cancer. We review various forms of immune-based therapies, which have shown significant promise in patients with hematological malignancies, including (i) conventional monoclonal therapies like rituximab, (ii) engineered monoclonal antibodies called bispecific T cell engagers (BiTEs), (iii) monoclonal antibodies and pharmaceutical drugs that block inhibitory T-cell pathways (i.e. PD-1, CTLA-4 and IDO), and (iv) adoptive cell transfer (ACT) therapy with T cells engineered to express chimeric antigen receptors (CARs) or T-cell receptors (TCRs). We also assess the idea of using these therapies in combination and conclude by suggesting multi-prong approaches to improve treatment outcomes and curative responses in patients.

show abstract

Antileukemic Effect of Interleukin-7-Transduced Bone Marrow Stromal Cells in Mice Following Allogeneic T-Cell-Depleted Bone Marrow Transplantation

Cited by 5 publications

References 6 publications

Interleukin-8 and Interleukin-17 for Cancer

Interleukin-8 and Interleukin-17 for Cancer

Interleukin-7 induced immunopathology in arthritis

Novel immunotherapies for hematologic malignancies

Contact Info

Product

Resources

About